Close menu




March 15th, 2021 | 07:18 CET

Palantir, Marble Financial, Deutsche Telekom - Investing in the gold of the future!

  • Investments
Photo credits: pixabay.com

Right now, we are living in a turning point of time. Digital transformation is generating more and more data. The future markets of artificial intelligence and machine learning enable entire industries to structure, analyze and evaluate vast amounts of data. Digital assistants, cooperative robots, autonomous vehicles and drones are products based on these technologies. Companies operating in these segments are currently still in the red. The capital that these startups are building at a high frequency is structured data, the gold of the 21st century.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: US69608A1088 , CA5660551097 , US2515661054

Table of contents:


    First Mover from Canada

    Marble Financial is a first mover in Canada when it comes to financial wellness. The market is huge; around one-third of the 36 million people in Canada do not have a bank account. In addition, there are about 137,000 insolvencies per year. The ever-increasing indebtedness of households and the monthly underfinancing are not only commonplace there. With the power of machine learning, data science and artificial intelligence on its proprietary "My Marble" platform, Marble Financial aims to solve this problem. Its current 3 technology solutions, Fast-Track, Score-Up and Maestro, aim to help consumers regain bank accounts and credit access.

    Continuous development

    With Score-Up, it is possible to analyze the customer's financing structure and income situation and use optimization tools to prescribe improvements. As a result, this increases the customer's credit score and the prospect of obtaining a loan from financial institutions. Fast-Track, on the other hand, offers a way for people who have slipped into personal insolvency to integrate back into the financial system. The Maestro eLearning platform is designed to teach consumers how to handle household accounts, loans and money in general. The ambitious fintech Company's next goal is to launch a secured credit card in collaboration with one of Canada's fifth-largest major banks. Also to be launched later this year is a tool that uses artificial intelligence to identify insolvencies early on from external customer data, filtering them out while recommending automated credit rehabilitation solutions.

    Strong collaborations

    Currently, Marble Financial is rolling out its SaaS platform through collaborations. It has partnered with LendforAll Canada, a lending platform with 25,000 borrowers, and Canadian Financial, which has over 200 lenders in its portfolio. This engagement allows Marble to make more connections with those who need help and accelerates its mission to help underserved people build financial futures. The Company, which trades in Germany and Toronto, has developed an innovative and promising technology with high economies of scale. An expansion into the USA, which has a similar financial system as the home market in Canada, is technically possible at any time. The market capitalization of Marble Financial is currently only EUR 11.7 million.

    End of the correction

    The data analysis specialist and market leader Palantir Technologies is already a completely different house number. The US Company, which lost more than 30% of its value in recent weeks due to its weaker than expected quarterly figures and the end of the lock-up period for existing shareholders, was able to announce another significant order. A six-year strategic partnership with Faurecia, one of the world's leading automotive technology companies, was announced.

    The Palantir Foundry platform will enable Faurecia to reduce raw material consumption, improve competitiveness in research and development, ensure optimized purchasing and track and analyze all steps towards CO2 neutrality. From a chart perspective, the situation around Palantir shares has also improved significantly. The sell-off ended at the test of the annual low of January at USD 22.50. This support was torn but was recovered in the course of trading. Currently, the data octopus is trading at USD 26.92 in volatile trading. A successful overcoming of the USD 30 mark would result in a price target of USD 38 again.

    Breakout successful

    The chart of Deutsche Telekom broke out on Friday. After a sideways movement lasting more than 5 years, the former people's share is preparing to climb to the multi-year high of EUR 18.15. Extremely positive analyst opinions triggered this. For months, it has been apparent that financial analysts have chosen the Bonn-based Company as their new favorite. Both the experts at Deutsche Bank and Berenberg continue to see Deutsche Telekom as a buy candidate. Berenberg sees EUR 22 as a fair value, while Deutsche Bank has written EUR 22.50 on the price tag.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read